NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity

Yifei Bao†, Xin Yang†, Yi Fu†, Zhengyan Li†, Ru Gong† and Wei Lu1,2,3*

Abstract

Background: β Amyloid (Aβ)-mediated neuronal hyperactivity, a key feature of the early stage of Alzheimer’s disease (AD), is recently proposed to be initiated by the suppression of glutamate reuptake. Nevertheless, the underlying mechanism by which the impaired glutamate reuptake causes neuronal hyperactivity remains unclear. Chronic suppression of the glutamate reuptake causes accumulation of ambient glutamate that could diffuse from synaptic sites at the dendrites to the soma to elevate the tonic activation of somatic N-methyl-D-aspartate receptors (NMDARs). However, less attention has been paid to the potential role of tonic activity change in extrasynaptic glutamate receptors (GluRs) located at the neuronal soma on generation of neuronal hyperactivity.

Methods: Whole-cell patch-clamp recordings were performed on CA1 pyramidal neurons in acute hippocampal slices exposed to TFB-threo-β-benzylxoyaspartic acid (TBOA) or human Aβ1–42 peptide oligomer. A series of dendritic patch-clamp recordings were made at different distances from the soma to identify the location of the changes in synaptic inputs. Moreover, single-channel recording in the cell-attached mode was performed to investigate the activity changes of single NMDARs at the soma.

Results: Blocking glutamate uptake with either TBOA or the human Aβ1–42 peptide oligomer elicited potentiation of synaptic inputs in CA1 hippocampal neurons. Strikingly, this potentiation specifically occurred at the soma, depending on the activation of somatic GluN2B-containing NMDARs (GluN2B-NMDARs) and accompanied by a substantial and persistent increment in the open probability of somatic NMDARs. Blocking the activity of GluN2B-NMDARs at the soma completely reversed both the TBOA-induced or the Aβ1–42-induced somatic potentiation and neuronal hyperactivity.

Conclusions: The somatic potentiation of synaptic inputs may represent a novel amplification mechanism that elevates cell excitability and thus contributes to neuronal hyperactivity initiated by impaired glutamate reuptake in AD.

Keywords: NMDA receptor, Hyperactivity, Somatic modification, Alzheimer’s disease

Background

Neuronal hyperactivity is a major pathology commonly present in a number of neurological disorders, including Alzheimer’s disease (AD) [1–3]. This featured electrophysiological change in neurons has been implicated in the development of several core symptoms of these diseases [4]. Notably, the aberrant neuronal activity in various neuropsychiatric states is often accompanied by...
deficits in glutamate transporters (GLTs) in glial cells, which result in the accumulation of ambient glutamate in the extracellular milieu [5], leading to the activation of additional glutamate receptors (GluRs) and thus potentiating the tonic activation of GluRs on surrounding neurons. This enhancement of activation of GluRs by ambient glutamate has been proposed to lead to neuronal hyperactivity [6]. Consistently, Aβ has been reported to induce metabolic disorder by jeopardizing glial cells and in turn lead to neuronal hyperactivity [7]. TFB-threo-β-benzylxoyaspartic acid (TBOA) is an unspecific glutamate uptake blocker that can elicit such accumulation of ambient glutamate and neuronal hyperactivity. Moreover, a recent study has demonstrated that local application of Aβ peptide to hippocampal CA1 neurons can mimic the effect of TBOA in inducing neuronal hyperactivity through initiating the suppression of glutamate reuptake [8]. Despite these findings, how deficits in GLT reuptake in glial cells contribute to neuronal hyperactivity remains largely unknown.

Glutamate is one of the most important neurotransmitters in the central nervous system. Ambient glutamate is implicated in several important neurological processes. Most previous studies have focused on how blockade of glutamate uptake affects synaptic events, including basal neurotransmission and synaptic plasticity [9, 10]. For example, the unspecific glutamate uptake blocker TBOA has been found to prolong the decay time of N-methyl-D-aspartate receptor (NMDAR)-mediated synaptic currents [11] via activation of perisynaptic NMDARs by elevated ambient glutamate. However, the effects of TBOA might be more widespread as extrasynaptic GluRs can also be activated by ambient glutamate [12]. A typical extrasynaptic domain for such receptors is the soma, where in general only a few inhibitory synapses innervate [13]. It is possible that following chronic suppression of the GLTs, the accumulated ambient glutamate could diffuse from synaptic sites at the dendrites to the soma to elevate the tonic activation of somatic NMDARs. However, less attention has been paid to the potential role of tonic activity change of extrasynaptic GluRs, especially GluRs at the subcellular domain proximal to the neuronal soma, in the generation of neuronal hyperactivity.

The elevated level of ambient extracellular glutamate has been shown to both constitutively activate and desensitize GluRs, especially GluRs at the extrasynaptic domains [14–16]. The exact sensitivity of GluR activation and desensitization depends on the GluR subtype [17]. Compared to the activation of AMPA and kainate receptors, the NMDAR activation is much more sensitive to changes in tonic glutamate level. NMDARs are composed of the obligatory GluN1 subunit and regulatory GluN2A-D or GluN3A-B subunits [18, 19]. Among these NMDAR subunits, the GluN2A and GluN2B subunits are essential to the properties of NMDAR. They have a relatively longer intracellular C-tail than the NR1 subunit, which enables them to interact with neighboring postsynaptic density proteins (PSD) [20]. Moreover, the GluN2A- and GluN2B-containing NMDARs are preferentially located at the synaptic and extrasynaptic sites, respectively [21]. Notably, the GluN2B-containing NMDARs (GluN2B-NMDARs) possess relatively higher sensitivities to glutamate and lower open probability than GluN2A-containing NMDARs (GluN2A-NMDARs) [22]. The different subtype distributions may therefore allow neurons to better integrate extrasynaptic inputs and respond to changes in the extracellular milieu. In acute hippocampal slices, for example, NMDARs in hippocampal CA1 pyramidal cells can be persistently activated by ambient extracellular glutamate [23, 24]. The tonic activation of NMDARs is also thought to primarily affect the cell excitability. For instance, the increase of the magnitude of tonic NMDAR currents which occurs with depolarization, due to the relief of voltage-gated Mg2+ blockade of NMDAR channels, can increase the tendency of the cell toward regenerative depolarization [25]. Previous findings have also suggested that the tonic NMDAR activity at the soma plays an important role in somatic generation of action potentials (APs). For example, bath application of a NMDAR blocker D,L-APV reduces the population spike recorded at the pyramidal cell layer where cell bodies of the pyramidal neurons are located, while having no effect on the field excitatory post-synaptic potentials (EPSPs) recorded in the dendritic region [24]. Since the population spike is a measure of the number of pyramidal cell discharges, this study suggests that the tonic activation of somatic NMDARs facilitates neuronal AP discharge at the soma.

As the neuronal soma receives very few excitatory glutamatergic inputs, NMDARs located at the soma are largely extrasynaptic GluN2B-NMDARs. Recently, we have revealed a novel plasticity rule that specifically occurs at the soma [30]. In this study, we set out to determine whether the elevated tonic activation of GluN2B-NMDARs at the soma, elicited by suppression of glutamate reuptake, employs a similar somatic potentiation mechanism to amplify dendritic inputs and in turn contributes to the induction of Aβ-mediated neuronal hyperactivity, which is believed to be associated with the circuit dysfunction that characterizes the early stages of AD.

Materials and methods

Acute hippocampal slice preparation

Male Sprague–Dawley rats of 2–3 weeks old were deeply anesthetized with ethyl ether and decapitated.
Brains were removed immediately and placed in ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM) 126 NaCl, 2.5 KCl, 1 CaCl2, 1 MgCl2, 1.25 KH2PO4, 26 NaHCO3, and 20 glucose, pH 7.2–7.4. Hippocampal coronal slices of 350-μm thick were obtained using a Leica VT1000 S vibrating blade microtome, transferred to warm (34 °C) ACSF and recovered for at least 1 h. ACSF solutions were bubbled with 95% O2/5% CO2 throughout the experiment. All experiments were performed in accordance with guidelines of Animal Care and Committee of Southeast University.

**Hippocampal slice recording**

EPSPs were recorded from acute brain slices in a current-clamp mode, with whole-cell recording using borosilicate glass pipettes containing (in mM) 135 K-gluconate, 5 KCl, 2 NaCl, 0.2 EGTA, 10 HEPES, 5 ATP, with pH adjusted to 7.2 by KOH. Bicuculline methiodide (BMI, 10 μM; Tocris, Bristol, England) was routinely added to the bath solution to block the type A gamma-aminobutyric acid (GABA_A) receptor-mediated inhibitory synaptic currents. Neurons in the CA1 stratum radiatum were identified under infrared differential
interference contrast (IR-DIC) video microscopy using an upright microscope (BX51WI, Olympus Corporation, Tokyo, Japan) and recorded with an Axopatch-700B amplifier (Molecular Devices, San Jose, CA). Data were sampled at 10 kHz and low-pass filtered at 2 kHz. The pipette resistances in the bath for somatic recording ranged 4–6 MΩ, and for dendritic patch recording ranged 12–15 MΩ. The series access resistance ranged 8–30 MΩ and was monitored during recording for fear of resealing of the ruptured membrane. Cells with changes in series access resistance >30 MΩ at any time during recordings were removed from the analysis. The amplitude of basal evoked EPSPs (eEPSPs) was set between 2 and 5 mV by adjusting the current intensity of test stimuli. For all plasticity experiments, the EPSP amplitude under the baseline condition was compared with that during the last 10 min of recording. Detailed data regarding the absolute values of membrane voltage, membrane resistance, and number of animals are provided for each experiment. For single-channel recordings, 50 μM NMDA and 35 μM glycine were used to elicit activities of NMDARs. The pipettes were filled with Mg²⁺-free ACSF, and patch-clamp was performed in a cell-attached mode. In order to puff NMDAR antagonist locally onto the soma or dendrite, Picospitzer (Intracell Co., England) was employed to control the speed, duration and pressure of puffings. Data were captured with the Clampex 10.4 software and analyzed using the Clampfit 10.4 software (Molecular Devices, San Jose, CA).

Aβ oligomerization and treatment solutions
Aβ₁₋₄₂ oligomers were prepared as described previously [26] and identified by Western blotting from a standard 15% SDS-PAGE, using an antibody against Aβ₁₋₄₂ (Cell Signaling Technology, Danvers, MA). The Aβ₄₋₁ peptide was prepared identically. In electrophysiology experiments, Aβ₁₋₄₂ aliquots were diluted into extracellular solutions to a final concentration of 500 nM.

Western blotting
Five microliters of either Aβ₁₋₄₂ oligomers or Aβ₄₋₁ peptide (80 μM) were mixed with 1× loading buffer and separated by 15% SDS-PAGE without boiling. Then they were transferred to nitrocellulose membranes. The membranes were blocked for 1 h in a solution of 3% (w/v) BSA diluted in TBS-T buffer (20 mM Tris/HCl [pH 7.4], 150 mM NaCl and 0.1% Tween-20), and incubated overnight with rabbit monoclonal antibody for Aβ₁₋₄₂ (D9A3A) (Cell Signaling Technology; 1:1000), which was produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human β-amyloid (1–42) peptide. HRP-conjugated goat anti-rabbit IgG (SunShine Bio, Nanjing, Jiangsu, China) was used as the secondary antibody (1:500). Finally, the signals were developed using the Super Signal West Pico Chemiluminescent Substrate kit (Thermo Fisher Scientific, Waltham, MA). Molecular mass was assessed by the Rainbow molecular weight markers (Bio-Rad, Hercules, CA).

Statistical analysis
Data were analyzed with Student’s t test or Kolmogorov–Smirnov tests using the SPSS software (IBM, Armonk, NY). Differences were regarded as significant when P<0.05.

Results
TBOA induces neuronal hyperactivity
As TBOA has been reported to mimic Aβ in the effect on both neuronal excitability and activity-dependent synaptic plasticity in vitro [8, 27, 28], we start with examining the effect of TBOA on the neuronal intrinsic excitability. Acute hippocampal slices were obtained from rats of postnatal 2–3 weeks of age. The whole-cell patch-clamp recordings were performed to detect membrane properties and cell excitability in CA1 pyramidal neurons. Persistent perfusion of TFB-TBOA (100 nM) led to progressive depolarization from resting membrane potential (RMP) in hippocampal CA1 neurons (ΔVmem, 4.84±0.16 mV, n=10 slices from 7 rats, P<0.01; Fig. 1a). The averaged RMP at baseline stage was −63.53±1.02 mV, and 30 min after TFB-TBOA treatment the membrane voltage was −58.69±0.33 mV. Compared to the RMP at the baseline stage, the hippocampal CA1 neurons attained 5 mV more depolarization at 30 min of TFB-TBOA (100 nM) treatment (Fig. 1a). This alteration in RMP was accompanied by an increase in the input resistance (Rin) in the same recorded cells (ΔRin, 113.13±4.50 MΩ, n=10 slices from 7 rats, P<0.01; Fig. 1b and Additional file 1: Fig. S1). The averaged Rin at baseline stage was 380.23±7.02 MΩ and that after 30 min of TFB-TBOA treatment was 493.35±10.79 MΩ. These results indicate that blockade of glutamate reuptake induces hippocampal CA1 neurons toward more depolarization.

To confirm the elevated level of excitation in recorded cells following TFB-TBOA treatment, we next determined both the threshold of AP generation and the firing rate in hippocampal CA1 neurons. We examined the possible change in AP threshold by injecting an epoch of current (600 ms) with different intensities (30, 50, 70 pA) in the recorded cells (Fig. 1c). Compared to controls, the TBOA-treated CA1 pyramidal cells displayed more firing spikes at the injection of the same intensity of current (Fig. 1d). In a separate set of experiments, we further
examined the firing rate in hippocampal CA1 neurons. Representative traces in Fig. 1e shows that the AP firing rate is very low under the baseline condition. However, GLT-1 blockade with TFB-TBOA (100 nM) substantially enhanced the AP firing rate from 0.03±0.02 to 1.68±0.22 Hz, which indicates significant potentiation in the firing rate of recorded cells ($n=8$ from 5 rats, $P<0.01$; Fig. 1g). Accordingly, cumulative probability distributions of spike intervals revealed a dramatic left-shift, suggesting a significant shortening of spike intervals ($P<0.01$; Fig. 1f). In conclusion, our results indicate that the GLT defunctionalization causes neuronal membrane depolarization and hyperactivity in hippocampal CA1 pyramidal cells, which is consistent with a previous finding [29].

**Neuronal hyperactivity depends on somatic NMDAR activity**

NMDAR hyperactivation is a characteristic feature in AD [28]. We next examined the possible role of NMDARs in the TBOA-induced neuronal hyperactivity. For this purpose, we repeated the above experiments on neuronal membrane properties under the condition that NMDAR activity was blocked by the NMDAR channel blocker MK-801 (50 µM). We found that application of MK-801 through whole-slice perfusion reversed the alterations of RMP and $R_{m}$ (RMP at baseline stage was $-69.13\pm0.38$ mV, and after 30 min of MK-801 treatment the membrane voltage was $-68.92\pm0.53$ mV; $R_{m}$ at baseline stage was $489.69\pm13.83$ MΩ and that after 30 min of MK-801 treatment was $487.86\pm17.25$ MΩ; $n=9$ from 7 rats; Fig. 2a, b), suggesting a crucial role of NMDARs in the TBOA-induced changes in membrane property.

It has been reported that under basal conditions, blockade of NMDARs at the soma rather than at the dendritic tree (where activated synapses locate) compromises the population spike generation [24]. As the population spike is a measure of the number of discharging pyramidal cells, this finding points to the notion that tonic activation of NMDARs at the soma plays an important role in somatic AP generation. To test whether tonic activation of NMDARs at the soma is responsible for the neuronal hyperactivity shown above, MK-801 (50 µM) was locally applied for 500 ms via pressure puffing to the soma of the recorded CA1 neurons (Fig. 2c, d). Notably, the TBOA-induced changes in RMP and $R_{m}$ were absent following MK-801 treatment, indicating total reversal of neuronal hyperactivity (RMP at baseline stage was $-65.53\pm0.15$ mV and 30 min after brief MK-801 treatment the membrane voltage was $-65.37\pm0.13$ mV; $R_{m}$ at baseline stage was $469.13\pm15.68$ MΩ and 30 min after brief MK-801 treatment $R_{m}$ was $479.65\pm15.71$ MΩ, $n=10$ from 7 rats). Collectively, these results highly suggest that the neuronal hyperactivity induced by GLT blockade depends on the activity of NMDAR at the soma.

In a separate set of experiments, we also investigated the possible changes in neuronal hyperactivity by examining the firing rate in hippocampal CA1 neurons. Consistently, we detected substantially enhancement in the AP firing rate following GLT-1 blockade with TFB-TBOA (100 nM), indicating that the firing rate of recorded cells was significantly potentiated ($1.4\pm0.09$ Hz, $n=5$ from 5 rats, $P<0.01$; Fig. 2e–j). The TBOA-induced potentiation in AP firing rate was, however, largely abolished by MK-801 (50 µM) either via whole-slice perfusion ($0.05\pm0.03$ Hz, $P<0.01$; Fig. 2e, g) or via local application on the soma ($0.15\pm0.09$ Hz, $n=6$ from 5 rats, $P<0.01$; Fig. 2h, j). Accordingly, the cumulative probability distributions of spike intervals revealed a dramatic right-shift, suggesting a significant prolongation of spike intervals ($P<0.01$, Fig. 2f, i).

Our results demonstrate the crucial role of NMDARs at the soma in TBOA-induced potentiation of AP firings. Next, we examined whether TBOA can also induce modification of the tonic current mediated by NMDARs located at the soma. For this purpose, we performed whole-cell recording in CA1 neurons while voltage-clamping these cells at $-45$ mV. The bath-applied TFB-TBOA (100 nM) induced an inward shift in $I_{holding}$ ($-24.60\pm4.38$ pA, $n=11$ from 7 rats; Fig. 2k, l), which could be partially reversed by local application of NMDAR antagonist MK-801 to the soma of recorded neurons ($12.61\pm2.34$ pA), suggesting that activation of somatic NMDARs contribute to the TBOA-induced enhancement in tonic currents.

**Somatic modification of dendritic inputs**

Our recent study reveals a unique form of plasticity rule that potentiates dendritic inputs selectively at the soma [30]. In particular, this somatic modification depends on the NMDAR activity at the soma. We thereby examined if GLT blockade could trigger the somatic NMDAR-dependent modification of dendritic inputs, which may in turn contribute to the neuronal hyperactivity observed following TFB-TBOA treatment. Hippocampal slices were perfused with the specific antagonist of GABA$_A$ receptor BMI (10 µM) to isolate evoked currents mediated by glutamate receptors. The eEPSPs were elicited by bipolar stimulating electrodes (made from the borosilicate theta glass) placed at a distance of 200 µm from the soma (Fig. 3a). The stimulating intensity was adjusted to produce eEPSPs at 2–5 mV. We found that the eEPSPs underwent a progressive and substantial potentiation following TBOA (100 nM) application (normalized potentiation magnitude, $1.84\pm0.04$, $n=7$ from 7 rats, $P<0.01$; Fig. 3b, c).
Fig. 2 The TBOA-induced changes in neuronal hyperactivity depend on the activation of NMDARs at the soma. a–d Time course and magnitude of the change in RMP (a, c) and input resistance (b, d). TFB-TBOA (100 nM) was applied via perfusing the slices (a, b) or via pressure puffing locally on the soma of recorded neurons (c, d). No significant changes in input resistance and RMP were observed after co-application of MK-801 (50 μM) and TFB-TBOA (100 nM). The blue-shaded area indicates the time period of TFB-TBOA treatment. Horizontal bars indicate drug application. The insets illustrate the local application of MK-801 via a pipette placed close to the soma of the recorded neuron. The arrow indicates the timepoint of somatic MK-801 application. e Example traces showing spontaneous firing of recorded CA1 pyramidal neurons before and after co-application of MK-801 and TFB-TBOA. Whole slice perfusion with MK-801 totally abolished the spontaneous firing. f Cumulative distribution of ISIs. g MK-801, when co-applied with TFB-TBOA, reversed the TBOA-induced potentiation in firing rate. h–j Same as in (e–g) except that MK-801 was locally applied on the soma. The duration of local MK-801 application was 500 ms. k Representative samples showing that blockade of GLTs (TFB-TBOA, 100 nM) induced an inward shift in the holding current and local application of MK-801 (50 μM) to the soma partially reversed the holding current. l Summary data of the shift of mean holding current. Data are means ± SEM. t test, **P < 0.01.
Fig. 3 TBOA elicits somatic amplification of dendritic inputs. 

**a** Illustration of stimulating and recording paradigm. Patch recordings were performed at the soma (I) or at the dendrites with different distances from the soma (II, 200 μm; III, 25 μm; IV, 10 μm). Low-frequency (0.1 Hz) basal stimulation was delivered at site II. 

**b** Sample traces showing the averaged EPSPs recorded at the soma or at the dendrites with different distances from soma. Sample EPSP traces are the average of 30 consecutive events recorded at the time marked by the numbers (1 or 2) from (c–f). 

**c–f** Graphs showing the time course and magnitude of the change in normalized EPSPs from a sample recording at the soma marked by I (c) or at dendrites located at different distances (marked by II, III, IV) from the soma (d–f). The TFB-TBOA (100 nM)-elicited potentiation in normalized EPSPs was only observed at the soma or at the dendrite located at site IV (10 μm distance) and was absent at site II (200 μm distance) or site III (25 μm). Notably, the potentiation magnitude in recordings at site IV (10 μm distance) was lower than that recorded at the soma. Left column, data from a sample recording. Right column, summary of results from all experiments. 

**g** Statistical histogram showing attenuation of TBOA-potentiated somatic EPSPs along the apical dendrite. Somatic EPSP potentiation was attenuated to the baseline level at apical dendrites within 25 μm from the soma. Data are means ± SEM. *t* test, *P* < 0.05; **P** < 0.01, ns, no significance.
To test whether the potentiation also occurs at the dendrite where the activated synapses are usually located, we performed serial patch-clamp recordings at the apical dendrite at different distances from the soma (Fig. 3d–f). We found that TFB-TBOA (100 nM) treatment did not produce any change in dendritic eEPSPs located at 200 μm (site II, normalized potentiation magnitude, 1.01 ± 0.03, n = 4 from 4 rats, P = 0.76; Fig. 3d) or 25 μm (site III, normalized potentiation magnitude, 1.07 ± 0.03, n = 4 from 4 rats, P = 0.15; Fig. 3e) from the soma, indicating the absence of EPSP potentiation even at the site closer to the soma. To identify the precise location of the eEPSPs potentiation, we further performed patch-clamp recordings at the apical dendrite at 10 μm distance from the soma (site IV; Fig. 3f). Notably, our recordings revealed a significant potentiation at this dendritic site (normalized potentiation magnitude, 1.46 ± 0.06, n = 4 from 4 rats, P < 0.01), which was however lower than that recorded at the soma (P < 0.05). Collectively, these results support the notion that the potentiation of synaptic inputs originates at the soma and undergoes progressive attenuation along the apical dendritic shaft away from the soma.

The small-conductance Ca\(^{2+}\)-activated K\(^+\) channels (usually known as SK channels) have been reported to couple to NMDARs both at the synapse and at the axonal dendrite [31, 32]. Therefore, it is possible that the TBOA-induced increase of permeability to Ca\(^{2+}\) through NMDARs activates SK channels and thus regulates hyperactivity. To test this, we performed a set of new experiments of serial patch in the presence of an SK channel blocker apamin (100 nM). A serial of patch recordings on the soma or on the dendrites at 10 μm and 200 μm distance from the soma revealed absence of effect of apamin on the TBOA-induced somatic amplification of dendritic inputs (Additional file 1: Fig. S2), suggesting that the SK channel is not involved in this process.

**Somatic modification depends on the GluN2B-NMDARs at the soma**

As the activity of NMDARs at the soma has recently been reported to be important for the somatic modification of dendritic inputs [30], we next tested whether the somatic modification caused by GLT blockade also depends on the activity of somatic NMDAR. Two minutes after TFB-TBOA treatment, MK-801 (50 μM) was applied to the soma with pressure injection for 500 ms to block the activity of somatic NMDARs (Fig. 4a). We found that this brief blockade of somatic NMDARs totally abolished the potentiation of eEPSPs elicited by TFB-TBOA treatment (normalized potentiation magnitude, 1.04 ± 0.03, n = 7 from 7 rats, P = 0.28; Fig. 4b–d). In a separate set of experiments, we additionally applied MK-801 (50 μM) via pressure injection to the dendrite that is proximal to the site of electrical stimulation. We found that this brief blockade of NMDAR activity at the stimulated dendrite failed to exert any significant influence on the potentiation of the dendritic input (normalized potentiation magnitude, 1.55 ± 0.04, n = 5 from 5 rats, P < 0.01; data on TBOA-induced EPSPs in Fig. 3c were used for comparison; Fig. 4b, e and f). Notably, the concentration of MK-801 used here was much higher than that usually used (1–10 μM). To verify whether MK-801 at 10 μM could exert similar blocking effect as that by 50 μM MK-801 (Additional file 1: Fig. S3), we repeated the experiments using 10 μM MK-801 to locally block the activity of NMDARs located at the soma. We found that under this condition the change in TFB-TBOA-induced potentiation in EPSPs could still be reversed in the recorded neurons (normalized potentiation magnitude, 1.06 ± 0.05, n = 5 from 4 rats). Another concern on MK-801 at 50 μM was that it might have multiple unspecific targets beyond NMDARs, including various calcium channels. To examine the possible involvement of calcium channels in the TFB-TBOA-induced potentiation of EPSPs, we monitored EPSPs during TFB-TBOA application in the presence of L-type calcium blocker nimodipine (10 μM) and T-type calcium blocker NiCl\(_2\) (100 μM) (Additional file 1: Fig. S4). No effects of the calcium channel blockers were observed, thus occluding the involvement of these calcium channels in the somatic potentiation of synaptic inputs. In other words, the inhibitory effect of 50 μM MK-801 on the somatic potentiation was not mediated by its action on calcium channels. Collectively, these results indicate that somatic modification induced by GLT blockade requires activation of NMDARs at the soma.

As the soma of hippocampal CA1 neurons receives very few excitatory synaptic inputs, most NMDARs located at the soma are extrasynaptic by definition and are mainly GluN2B-NMDARs [21]. We next tested whether the somatic modification of dendritic inputs selectively depends on the GluN2B-NMDARs at the soma. For this purpose, we pressure-puffed the selective antagonist of GluN2B-NMDARs, ifenprodil (3 μM), on the soma shortly after TFB-TBOA treatment. Again, this brief blockade of GluN2B-NMDARs completely abolished the potentiation of eEPSPs (normalized potentiation magnitude, 1.00 ± 0.04, n = 6 from 6 rats, P = 0.77; Fig. 4g–i). In contrast, the antagonist of GluN2A-NMDARs, NVP-AAM077 (125 pM), failed to display any significant effect on TBOA-induced potentiation of eEPSPs (normalized potentiation magnitude, 1.63 ± 0.04, n = 6 from 6 rats, P < 0.01; Fig. 4g, j, k). Taken together, our data support that the somatic potentiation of dendritic inputs depends on the activation of GluN2B-NMDARs at the soma.
Fig. 4  Somatic amplification of dendritic inputs depends on the activity of GluN2B-NMDARs located at the soma.  

a. Illustration of stimulating and recording paradigm. Note that the MK-801 was either locally applied to the soma or to the dendrite of the recorded neuron where the stimulating electrode was placed (200 μm distance from the soma).  
b. Sample traces showing averaged EPSPs recorded at the soma or at dendrites in hippocampal CA1 pyramidal neurons. Sample EPSP traces are the average of 30 consecutive events recorded at the time marked by the numbers (1 or 2) from c–f. MK-801 (50 μM) was locally applied with TFB-TBOA (100 nM) either at the soma or at the dendrite.  
c–f MK-801 applied at the soma totally abolished the TBOA-elicited EPSP potentiation. c, e Results from a single experiment displaying the time course and magnitude of the normalized EPSPs. d, f Summary of results from all experiments as that in (c) and (e), respectively. MK-801 applied to the dendrite failed to affect the TBOA-induced potentiation in normalized EPSPs, while MK-801 applied to the soma reversed the EPSP potentiation induced by TBOA.  
g–k Antagonist of GluN2B-NMDARs, but not of GluN2A-NMDARs applied at the soma, totally abolished the TBOA-elicited EPSP potentiation. Results from a single experiment (h, j) and summarized results (i, k) displaying the time course and the magnitude of the normalized EPSPs.  
l. Statistical histogram showing the effect of locally applied NMDAR antagonists. MK-801 (50 μM) or ifenprodil (3 μM) applied to the soma totally reversed the TBOA-induced EPSP potentiation. Data are means ± SEM, t test, **P < 0.01
Aβ-mediated neuronal hyperactivity depends on the elevated somatic NMDAR activation

Amyloid plaques are the pathological hallmark of AD, and extensive research has identified a causal link of Aβ to AD [33–37]. Numerous studies have also indicated that the impairment of GLTs could be another key feature of AD [38, 39]. These two symptoms are inter-related as the Aβ1–42 peptide can slow down the clearance of synaptically released glutamate by inducing mislocalization of astrocytic GLT-1, the major GLT in the adult brain [40], a process which has been employed to model several aspects of AD [41]. Recently, an elegant study has reported that the Aβ-mediated suppression of GLT contributes to the generation of APs at the soma [24]. GLT dysfunction in glial cells leads to accumulation of glutamate at the soma of recorded neurons (0.09 from 6 rats; TBOA: 0.20 ± 0.02, n = 5 from 4 rats, P < 0.01; Fig. 5j). Notably, this enhancement in NMDAR opening probability persisted either for at least 30 min after TBOA treatment or 2 h after Aβ1–42. These findings indicate that GLT blockade improves sustained opening of somatic NMDARs.

Aβ-mediated somatic potentiation of dendritic inputs

As Aβ initiates the suppression of GLT as TBOA does, we examined whether Aβ can mimic TBOA’s effect by potentiating dendritic inputs at the soma (Fig. 6a). The acute hippocampal slices perfused with Aβ1–42 peptide (500 nM) yielded a progressive enhancement of evoked dendritic inputs (normalized potentiation magnitude, 1.77 ± 0.03, n = 7 from 7 rats, P < 0.01 Fig. 6b–d), indicating that Aβ1–42 treatment can potentiate dendritic inputs.

To further examine whether the Aβ1–42-mediated potentiation of dendritic inputs occurs at the dendrite where synaptic inputs were activated, we next performed patch-clamp recording at the dendrite proximal to the stimulating electrode (< 10 μm; Fig. 6a). The eEPSPs recorded at the stimulated dendrites 200 μm from the soma failed to exhibit any significant change during Aβ1–42 treatment (normalized potentiation magnitude, 0.98 ± 0.03, n = 4 from 4 rats, P < 0.01; Fig. 6b, e, f), suggesting that the modification of dendritic inputs occurred at the soma rather than the dendrite.

We further examined whether the Aβ1–42-mediated potentiation of dendritic inputs depended on the activation of NMDARs at the soma. As the TBOA-induced somatic potentiation of dendritic inputs depended on the activation of GluN2B-NMDARs at the soma, we performed a similar experiment by locally applying a GluN2B-NMDARs blocker ifenprodil (3 μM) to the soma of the recorded neurons 2 min after Aβ1–42 (500 nM) treatment (Fig. 6g). Similar to the previous findings, the Aβ1–42-induced somatic potentiation of dendritic inputs was totally abolished by ifenprodil treatment (normalized potentiation magnitude, 1.02 ± 0.02, n = 6 from 5 rats, P = 0.47; Fig. 6h, i). These results suggest that the Aβ1–42-induced potentiation of dendritic inputs depends on the activation of GluN2B-NMDARs located at the soma.

Aβ at 500 nM concentration induces somatic potentiation of synaptic inputs. Is this an all-or-none mechanism or is it dependent on the concentration of Aβ? To address this question, we performed a dose–response study in the key experiments and found that Aβ1–42 at 100 nM elicited potentiation of EPSPs with 1.29 ± 0.03 potentiation magnitudes (Fig. 6j–k). The Aβ1–42 peptide oligomer within the concentration range of 200–1000 nM (200, 500, 1000 nM) elicited potentiation of EPSPs with similar potentiation magnitudes (P > 0.05 among the concentrations, t test), indicating a stable potentiation magnitude at Aβ1–42 concentration of 200 nM and above. In
contrast, Aβ1-42 at 50 nM failed to display any effect on EPSPs. Moreover, the magnitude of Aβ-induced potentiation was comparable to that induced by TBOA at 100 nM (Fig. 6l). These results indicate the incremental effect of Aβ1-42 is not an all-or-none mechanism but depends on the dosage of Aβ1-42.

Combined with the results in Fig. 5 showing the dependency of Aβ-mediated neuronal hyperactivity
Fig. 6  Aβ-mediated somatic potentiation of dendritic inputs. a Illustration of the stimulating and recording paradigm. Patch-clamp recordings were performed in the current-clamp mode either at the soma or at the dendrite (200 μm distance from the soma) proximal to the stimulating electrode. b Averaged sample traces recorded at the soma, showing EPSPs before and after Aβ₁-₄₂ peptide (500 nM) treatment. Potentiation of EPSPs was only detected when patch recording was performed at the soma, but not at the dendrite. c-f Graphs showing the time course and magnitude of the change in normalized EPSPs recorded at the soma (c, d) and at the dendrite where synaptic inputs were activated by stimulating electrode (e, f). d, f Summary of results from all experiments as that shown in (c) and (e), respectively. g Illustration of local application (pressure puffing) of GluN2B-NMDAR blocker ifenprodil (3 μM) to the soma. Whole-cell patch-clamp recording was performed at the soma while stimulation was delivered at the dendrite. h Aβ₁-₄₂-induced EPSP potentiation was reversed by the GluN2B-NMDAR blocker ifenprodil (3 μM) that was locally applied to the soma. Ifenprodil (3 μM) was applied 2 min after Aβ₁-₄₂ (500 nM) treatment. i Statistical histogram showing the dependency of the Aβ₁-₄₂-induced EPSP potentiation on the activity of somatic GluN2B-NMDARs. j Effects of Aβ₁-₄₂ at different concentrations on the potentiation of synaptic inputs. k Summarized dose–response data. l Similar potentiation effects produced by 100 nM TBOA and 500 nM Aβ₁-₄₂. Data are means ± SEM, **P < 0.01, t test; ns, no significance.
on elevated somatic NMDAR activation, these data suggest that the enhancement of sustained activation of NMDARs at the soma is the key mediator of the production of both somatic plasticity and hyperactivity. The somatic GluN2B-NMDAR-dependent potentiation mechanism is not only highly associated with but may also contribute to the Aβ-mediated neuronal hyperactivity.

**Discussion**

By employing patch-clamp recordings on the soma or apical dendrite of the hippocampal CA1 pyramidal neurons, we revealed in the present study that the somatic potentiation of dendritic inputs may contribute to the neuronal hyperactivity caused by the impairment of glutamate reuptake. This somatic potentiation was accompanied by elevated tonic activity of NMDARs located at the soma. We further illustrated that the increased NMDAR activity at the soma is essential to the somatic potentiation of dendritic inputs. Lastly, we examined these effects in the context of Aβ₁₋₄₂ administration and found similar neural hyperactivity dependent on the NMDAR activity. This not only affirms the association between neural hyperactivity and amyloid plaques commonly observed in neurodegenerative diseases, but also suggests a novel pathological perspective that specifically involves the GluN2B-NMDAR-mediated potentiation at the soma.

**Deficit of GLT and neuronal hyperactivity in AD**

Under normal circumstances, ambient extracellular glutamate is generally maintained at a relatively low level to ensure synaptic transmission with appropriate signal-to-noise ratio and to prevent excessive activation of GluRs. The appropriate amount of ambient glutamate is maintained by GLTs in glial cells via glutamate reuptake. Down-regulation of certain excitatory amino acid transporters (EAATs), such as GLT1, is often reported in various neuropsychiatric diseases such as epilepsy, stroke, AD, depression and movement disorders [3, 4]. Meanwhile, neuronal hyperactivity is also frequently observed in these neurological diseases [7, 42, 43]. Based on the excitatory nature of ambient glutamate, the causal link between GLT deficit and neuronal hyperactivity has been proposed [6]. As the down-regulation of EAATs causes accumulation of ambient glutamate at the extracellular milieu, which would likely in turn activate additional GluRs, we speculate that the changes in the membrane properties and the excitability of cells surrounded by the elevated ambient glutamate may contribute to the neuronal hyperactivity observed in various neuropsychiatric states.

In the present study, we determined the alterations of RMP, input resistance, spontaneous firing rate and threshold of AP generation in hippocampal CA1 pyramidal neurons following GLT blockade, and found progressive depolarization from RMP and increase in input resistance. Consistently, a substantial increase in the spontaneous spike firing and a dramatic decrease in the threshold of AP generation were also observed. Collectively, these results suggest that the changes in membrane and cell excitability are responsible for the neuronal hyperactivity elicited by down-regulation of GLT. Interestingly, all these changes induced by GLT blockade were totally reversed by pressure application of the NMDAR open channel blocker MK-801 onto the soma, pointing to a crucial role of somatic NMDAR activation in the generation of neuronal hyperactivity. We speculate that following chronic suppression of the GLTs, the accumulated ambient glutamate could diffuse from the synapse-rich dendrites to the soma to improve the tonic activation of somatic NMDARs.

**Tonic activation of somatic NMDARs and somatic potentiation of dendritic inputs**

Currently, the widely accepted etiology for AD is that Aβ perturbs both synaptic transmission and plasticity [9, 10]. In the hippocampus of AD mice, for instance, enhanced neuronal activity has been detected [1, 2]. This neuronal overexcitation is related to the elevation of intracellular calcium concentration [44, 45]. On the other hand, Aβ oligomer has been reported to suppress the surface expression of NMDARs [46], hippocampal LTP, and learning and memory [47–49]. Notably, recent studies have further revealed that the Aβ-induced inhibition of LTP can be reversed by blocking extrasynaptic GluN2B-NMDARs, pointing to a more important role of extrasynaptic NMDARs in the production of abnormal plasticity [28, 50].

Here, we further demonstrated that the extrasynaptic NMDARs at the soma play a crucial role in both neuronal hyperactivity and correlated somatic potentiation. As Aβ suppresses GLT in glial cells, the accumulated ambient glutamate can lead to both tonic activation and desensitization of GluRs. We hypothesized that this effect may be mainly mediated by GluN2B-NMDARs. The GluN2B-NMDAR is not only more sensitive to glutamate compared to most other subtypes, but also preferentially located extrasynaptically at the soma [17, 22]. These somatic NMDARs are tonically activated by basal ambient glutamate [23, 24], an activity that has been shown to facilitate neuronal discharge at the soma and potentially contribute to the long-term hyperactivity [24, 30]. Consistent with our hypothesis, GLT suppression with TBOA...
or Aβ induced a substantial increment in NMDAR open probability at the soma and that such potentiation was totally reversed by somatic pressure applications of antagonists of GluN2B- (ifenprodil), but not of GluN2A-NMDARs. These findings provide evidence to support the correlation between somatic NMDAR activation and somatic potentiation of dendritic inputs, specifically unveiling the role of extrasynaptic GluN2B-NMDARs in neuronal hyperactivity. In addition, these results are consistent with our recent finding that dendritic inputs can undergo persistent modifications at the soma [30], which indicates a novel form of plasticity that also depends on the sustained activity of NMDAR at the soma. More importantly, in that study we have demonstrated that elevating the activation of somatic NMDARs by puffing NMDA to the soma is sufficient to induce somatic amplification of dendritic inputs. In this sense, the Aβ-induced somatic plasticity we revealed here could be a causative factor for neuronal hyperactivity in AD.

Based on the current results, we propose that the accumulated ambient glutamate caused by GLT blockade promotes the tonic NMDAR activity at the soma and in turn triggers a novel somatic amplification mechanism that accounts for the neuronal hyperactivity initiated by impaired glutamate reuptake in AD. The present findings drag our sight from synaptic to extrasynaptic compartment at the soma for the first time to illustrate the mechanisms underlying the Aβ-dependent neuronal hyperactivity. Future studies may seek the exact causal relationship between elevated glutamate tone, somatic NMDAR activation and neuronal hyperactivity by focal manipulations of glutamate levels or receptor functionality at the soma. Understandings of the somatic involvement in the overall electrophysiological activities of a neuron may shed light on how extracellular environment influences normal functionality and provide new therapeutic targets for amyloid plaque-induced pathologies.

Conclusions
Our results reveal that suppression of glutamate uptake with either TBOA or human Aβ1-42 oligomer can elicit a novel form of neural plasticity that selectively occurs at the soma of CA1 hippocampal neurons. The somatic amplification of synaptic inputs may help elevate the cell excitability and thus contribute to the neuronal hyperactivity initiated by impaired glutamate reuptake in AD.

Abbreviations
Aβ: β Amyloid; AD: Alzheimer’s disease; GluRs: Glutamate receptors; TBOA: TFB-threo-β-benzyloxyaspartic acid; NMDARs: N-methyl-D-aspartate receptors; GluN2B-NMDARs: GluN2B-containing NMDARs; GLTs: Glutamate transporters; EPSPs: Excitatory post synaptic potentials.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40035-021-00260-3.

Acknowledgements
We thank all members of the Lu lab for discussion and support. We also thank Ms. He Yang for help on editing of the manuscript.

Authors’ contributions
YB, XY, YF, ZL, RS performed the experiments; YB performed statistics, WL designed and wrote the paper. All authors read and approved the final manuscript.

Funding
This work was supported by grants to WL from the National Natural Science Foundation of China (31730107, 31970959, 31671056).

Availability of data and materials
The datasets used and/or analysed in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Animal experimental procedures were approved by the Animal Care and Use Committee of Southeast University.

Consent for publication
All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Author details
1 MOE Key Laboratory of Developmental Genes and Human Disease, School of Life Science and Technology, Southeast University, Nanjing 210096, China.
2 Department of Neurology, Huashan Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontier Center for Brain Science, Fudan University, Shanghai 200032, China. 3 Co-Innovation Center of Neuoregeneration, Nantong University, Nantong 226001, China.

Received: 7 April 2021 Accepted: 12 August 2021 Published online: 08 September 2021

References
1. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007;55:697–711
2. Šišková Z, Justus D, Kaneko H, Friedrichs D, Henneberg N, Beutel T, et al. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer’s disease. Neuron. 2014;84:1023–33
3. Soni N, Reddy BV, Kumar P. GLT-1 transporter: an effective pharmacological target for various neurological disorders. Pharmacol Biochem Behav. 2014;127:70–81.
4. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333–55.
5. Tzingounis AV, Wadiche JI. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci. 2007;8:935–47.

6. Pal B. Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability. Cell Mol Life Sci. 2018;75:2917–49.

7. Ovsepian SV, Blazquez-Llorca L, Freitag SV, Rodrigues EF, Herms J. Ambi- glutamate promotes paroxysmal hyperactivity in cortical pyramidal neurons at amyloid plaques via presynaptic mGluR1 receptors. Cereb Cortex. 2017;27:4733–49.

8. Zott B, Simon MM, Hong W, Unger F, Frosch MP, et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science. 2019;365:559–65.

9. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–91.

10. Small DH, Mok SS, Bornstein JC. Alzheimer’s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2002;3:595–8.

11. Tsukada S, Ino M, Takayasu Y, Shimamoto K, Ozawa S. Effects of a novel glutamate transporter blocker, (2S, 3S)-3-[3-[4-(trifluoromethyl)benzo- ylaminobenzoyl])aspartate (TFA-BTAO), on activities of hippocampal neurons. Neuropsychopharmacology. 2005;48:479–91.

12. Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuroon. 2014;82:279–93.

13. Petralia RS, Kogelsberger T, Shepherdson ND, Mennerick S. Ambi- glutamate transporter blockers prevent Abeta oligomers from activating long-term depression in rat dentate gyrus. Brain Res. 2002;924:133–40.

14. Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, et al. Organization of NMDA receptors at extrasynaptic locations. Neuroscience. 2010;167:68–87.

15. Nahum-Levy R, Lipinski D, Shavit S, Benveniste M. Desensitization of NMDA receptor channels is modulated by glutamate agonists. Biophys J. 2001;80:2152–66.

16. Sather W, Dieudonnel S, MacDonald JF, Fischer P. Activation and desen- sitization of N-methyl-D-aspartate receptors in nucleated outside-out patches from mouse neurons. J Physiol. 1992;450:643–72.

17. Zorovski CF, Mennerick S, Que J. Modulation of excitatory synaptic trans- mission by low concentrations of glutamate in cultured rat hippocampal neurons. J Physiol. 1996;494(Pt 2):465–77.

18. Featherstone DE, Shippy SA. Regulation of synaptic transmission by ambient extracellular glutamate. Neuroscientist. 2008;14:171–81.

19. Perez-Otano I, Sluetts CT, Contractor A, Lipton SA, Trimmer JS, Sucher TJ, et al. Aberrant detergent-insoluble excitatory amino acid trans- porter 2 accumulates in Alzheimer disease. J Neurorhop Exp Neurol. 2010;69:676–77.

20. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synthetically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci. 2013;33:5312–8.

21. O’Neillab À, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid beta-protein dimers rapidly form stable synaptic trophoblasts. J Neurosci. 2010;30:14411–9.

22. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity. impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383–400.

23. Le Meur K, Galante M, Angulo MC, Audinat E. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J Physiol. 2007;580:373–83.

24. Sah P, Hestrin S, Nicoll RA. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. Nature. 1994;368:144–7.

25. Cavelier P, Hamann M, Rossi D, Mobbs P, Attwell D. Tonic excitation and inhibition of neurons: ambient transmitter sources and computational consequences. Prog Biophys Mol Biol. 2005;87:3–16.

26. Caballero E, Calvo-Rodriguez M, Gonzalo-Ruiz AV, Villalobos C, Núñez L. A new procedure for amyloid β oligomers preparation enables the unam- biguous testing of their effects on cytosolic and mitochondrial Ca2+(+) cell entry and cell death in primary neurons. Neurosci Lett. 2016;612:66–73.

27. Li S, Hong S, Shepherdson NE, Shankar GM, Selkoe D. Soluble oli- gomers of amyloid β protein facilitate hippocampal long-term depres- sion by disrupting neuronal glutamate uptake. Neuron. 2009;62:788–801.

28. Li S, Jin M, Kogelsberger T, Shepherdson NE, Shankar GM, Selkoe DJ. Soluble β-amyloid oligomers inhibit long-term potentiation through a mecha- nism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627–38.

29. Molinari F, Cattani AA, Mdzomba JB, Anisikstejn L. Glutamate transporters control metabotropic glutamate receptors activation to prevent the gen- gis of paroxysmal burst in the developing hippocampus. Neurosciencio. 2012;207:25–36.

30. Yang X, Yao Y, Xu J, Gong R, Zhang N, Cai L, et al. Long-lasting somatic modifications of convergent dendritic inputs in hippocampal neurons. Cereb Cortex. 2020;30:1436–46.

31. Köhler M, Hirschberg B, Bond CT, Kinzie JM, Marrión NV, Mayle J, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273:1709–14.

32. Marrión NV, Tavallini SJ. Selective activation of Ca2+-activated K+ chan- nels by co-localized Ca2+-4 channels in hippocampal neurons. Nature. 1998;395:900–5.

33. Citron M, Oltersdorff T, Haass C, McConlogue A, HungAY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature. 1992;360:672–4.

34. Citron M, Winstawday D, Xiao W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67–72.

35. Stine WB Jr, Dahlgren KN, Kraffta GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612–22.

36. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993;259:514–6.

37. Goate A, Chartier-Harlin MC, Mullan B, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–6.

38. Scott HA, Gebhardt FM, Minovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer’s disease. Neurobiol Aging. 2011;32(5S3):e651–e651.

39. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid trans- porter 2 accumulates in Alzheimer disease. J Neurorhop Exp Neurol. 2010;69:676–77.

40. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synthetically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci. 2013;33:5312–8.

41. O’Neillab À, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid beta-protein dimers rapidly form stable synaptic trophoblasts. J Neurosci. 2010;30:14411–9.

42. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Augerean G, et al. In vivo expression of polyglutamine-expanded huntingtin in mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet. 2010;19:3053–67.

43. Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma. 2013;30:1434–41.

44. Busche MA, Eichhoff G, Adelberger H, Abramowski D, Wiedehold KH, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science. 2008;321:1686–9.

45. Kuchibhotla KV, Lattarulo CR, Hyman BT, Backsail BJ. Synchronous hyper-activity and intercellular calcium waves in astrocytes in Alzheimer mouse. Science. 2009;323:1211–5.

46. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051–8.

47. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brain. Nature. 1998;395:900–5.